Fig. 6: Longitudinal changes of sBCMA in patients treated with CS1-BCMA CAR-T cells.
From: Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma
A Longitudinal change of sBCMA in peripheral blood (PB) of patients with stringent complete response (sCR), very good partial response (VGPR)/partial response (PR), and nonresponse (NR)/ progressive disease (PD). B Longitudinal changes of sBCMA in bone marrow (BM) of patients with sCR and VGPR/PR. Three patients with solitary extramedullary diseases did not respond and their BM samples were not accessible. C Longitudinal changes of sBCMA in peripheral blood (PB) of individual patients. Gray dashed line indicated the lower detection limit of sBCMA (6.25 ng/mL) and red dashed line indicated the upper limit of normal value (75.35 ng/mL). D, E Baseline levels and the reduction ratio of sBCMA in month 1 relative to the baseline in PB and BM of patients with different clinical response. One-way ANOVA was used for PB samples and unpaired t test was used for BM samples. Pt patient, M month.
